Katzmann, Julius L.
Stürzebecher, Paulina E.
Kruppert, Silvia
Laufs, Ulrich
Funding for this research was provided by:
Daiichi Sankyo
Universitätsklinikum Leipzig
Article History
Received: 23 October 2023
Accepted: 27 December 2023
First Online: 4 January 2024
Competing interests
: JLK has received consulting fees and travel grants from Daiichi Sankyo. PES has received speaker honoraria from Amgen and Novartis. SK is an employee of IQVIA, which received funding from Daiichi Sankyo for conducting the analysis. UL has received speaker honoraria from Amgen, Daiichi Sankyo, Novartis, and Sanofi. This study was funded by Daiichi Sankyo Europe GmbH, which is marketing authorisation holder of Nilemdo<sup>®</sup> and Nustendi<sup>®</sup> in the UK, European Economic Area, and Switzerland.